Commentary Open Access
Volume 3 | Issue 6 | DOI: https://doi.org/10.33696/immunology.3.122
Targeting Ovarian Cancer with IL-2 Cytokine/Antibody Complexes: A Summary and Recent Advances
Yilun Deng1, Ryan M Reyes2,3, Chenghao Zhang1,4, José Conejo-Garcia5, Tyler J. Curiel1,2,3,6,*
- 1Discipline of Pharmacology, School of Pharmacy, University of the Western Cape, Bellville 7535, South Africa
- 2Department of Chemistry, University of the Western Cape, Bellville 7535, South Africa
- 3South African Herbal Science and Medicine Institute, University of the Western Cape, Bellville 7535, South Africa
- 4Discipline of Pharmaceutics, School of Pharmacy, University of the Western Cape, Bellville 7535, South Africa
- 5South African Herbal Science and Medicine Institute, University of the Western Cape, Bellville 7535, South Africa
- 6Discipline of Pharmaceutics, School of Pharmacy, University of the Western Cape, Bellville 7535, South Africa
Corresponding Author
Tyler Curiel, curielt@uthscsa.edu
Received Date: August 12, 2021
Accepted Date: December 04, 2021
Citation:
Deng Y, Reyes RM, Zhang C, Conejo-Garcia J, Curiel TJ. Targeting Ovarian Cancer with IL-2 Cytokine/Antibody Complexes: A Summary and Recent Advances. J Cell Immunol. 2021;3(6):387-396.
Copyright: © 2021 Deng Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
Ovarian cancer, Immunotherapy, IL-2, Regulatory T cell, IL-2 receptor